These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33372680)

  • 21. Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition.
    Hughes E; Wagner S; Pruss D; Bernhisel R; Probst B; Abkevich V; Simmons T; Hullinger B; Judkins T; Rosenthal E; Roa B; Domchek SM; Eng C; Garber J; Gary M; Klemp J; Mukherjee S; Offit K; Olopade OI; Vijai J; Weitzel JN; Whitworth P; Yehia L; Gordon O; Pederson H; Kurian A; Slavin TP; Gutin A; Lanchbury JS
    JCO Precis Oncol; 2022 Nov; 6():e2200084. PubMed ID: 36331239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of polygenic risk scores for prediction of breast cancer and breast cancer subtypes in Chinese women.
    Hou C; Xu B; Hao Y; Yang D; Song H; Li J
    BMC Cancer; 2022 Apr; 22(1):374. PubMed ID: 35395775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers.
    Ghunaim H; Laenen A; De Keyzer F; Soens J; Keupers M; Postema S; Neven P; Van Ongeval C
    Eur J Radiol; 2022 Jan; 146():110074. PubMed ID: 34902667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
    Kriege M; Hollestelle A; Jager A; Huijts PE; Berns EM; Sieuwerts AM; Meijer-van Gelder ME; Collée JM; Devilee P; Hooning MJ; Martens JW; Seynaeve C
    Br J Cancer; 2014 Aug; 111(5):1004-13. PubMed ID: 24918820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
    Liu Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    BMC Cancer; 2015 Mar; 15():194. PubMed ID: 25884806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of genome-wide polygenic risk scores for predicting breast cancer incidence in Japanese females: a population-based case-cohort study.
    Ohbe H; Hachiya T; Yamaji T; Nakano S; Miyamoto Y; Sutoh Y; Otsuka-Yamasaki Y; Shimizu A; Yasunaga H; Sawada N; Inoue M; Tsugane S; Iwasaki M;
    Breast Cancer Res Treat; 2023 Feb; 197(3):661-671. PubMed ID: 36538246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polygenic risk scores for prediction of breast cancer risk in Asian populations.
    Ho WK; Tai MC; Dennis J; Shu X; Li J; Ho PJ; Millwood IY; Lin K; Jee YH; Lee SH; Mavaddat N; Bolla MK; Wang Q; Michailidou K; Long J; Wijaya EA; Hassan T; Rahmat K; Tan VKM; Tan BKT; Tan SM; Tan EY; Lim SH; Gao YT; Zheng Y; Kang D; Choi JY; Han W; Lee HB; Kubo M; Okada Y; Namba S; ; Park SK; Kim SW; Shen CY; Wu PE; Park B; Muir KR; Lophatananon A; Wu AH; Tseng CC; Matsuo K; Ito H; Kwong A; Chan TL; John EM; Kurian AW; Iwasaki M; Yamaji T; Kweon SS; Aronson KJ; Murphy RA; Koh WP; Khor CC; Yuan JM; Dorajoo R; Walters RG; Chen Z; Li L; Lv J; Jung KJ; Kraft P; Pharoah PDB; Dunning AM; Simard J; Shu XO; Yip CH; Taib NAM; Antoniou AC; Zheng W; Hartman M; Easton DF; Teo SH
    Genet Med; 2022 Mar; 24(3):586-600. PubMed ID: 34906514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction.
    Hovhannisyan M; Zemankova P; Nehasil P; Matejkova K; Borecka M; Cerna M; Dolezalova T; Dvorakova L; Foretova L; Horackova K; Jelinkova S; Just P; Kalousova M; Kral J; Machackova E; Nemcova B; Safarikova M; Springer D; Stastna B; Tavandzis S; Vocka M; Zima T; Soukupova J; Kleiblova P; Ernst C; Kleibl Z; Janatova M
    Cancer; 2024 Sep; 130(17):2978-2987. PubMed ID: 38718029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
    Stolarova L; Kleiblova P; Zemankova P; Stastna B; Janatova M; Soukupova J; Achatz MI; Ambrosone C; Apostolou P; Arun BK; Auer P; Barnard M; Bertelsen B; ; Blok MJ; Boddicker N; Brunet J; Burnside ES; Calvello M; Campbell I; Chan SH; Chen F; Chiang JB; Coppa A; Cortesi L; Crujeiras-González A; ; De Leeneer K; De Putter R; DePersia A; Devereux L; Domchek S; Efremidis A; Engel C; Ernst C; Evans DGR; Feliubadaló L; Fostira F; Fuentes-Ríos O; Gómez-García EB; González S; Haiman C; Hansen TVO; Hauke J; Hodge J; Hu C; Huang H; Ishak NDB; Iwasaki Y; Konstantopoulou I; Kraft P; Lacey J; Lázaro C; Li N; Lim WK; Lindstrom S; Lori A; Martinez E; Martins A; Matsuda K; Matullo G; McInerny S; Michailidou K; Montagna M; Monteiro ANA; Mori L; Nathanson K; Neuhausen SL; Nevanlinna H; Olson JE; Palmer J; Pasini B; Patel A; Piane M; Poppe B; Radice P; Renieri A; Resta N; Richardson ME; Rosseel T; Ruddy KJ; Santamariña M; Dos Santos ES; Teras L; Toland AE; Trentham-Dietz A; Vachon CM; Volk AE; Weber-Lassalle N; Weitzel JN; Wiesmuller L; Winham S; Yadav S; Yannoukakos D; Yao S; Zampiga V; Zethoven M; Zhang ZW; Zima T; Spurdle AB; Vega A; Rossing M; Del Valle J; De Nicolo A; Hahnen E; Claes KBM; Ngeow J; Momozawa Y; James PA; Couch FJ; Macurek L; Kleibl Z
    Clin Cancer Res; 2023 Aug; 29(16):3037-3050. PubMed ID: 37449874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.
    Liu Y; Liao J; Xu Y; Chen W; Liu D; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu X; Xie Y
    Hum Mutat; 2011 Sep; 32(9):1000-3. PubMed ID: 21618645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of coding germline variants on contralateral breast cancer risk and survival.
    Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
    Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.
    Du Z; Gao G; Adedokun B; Ahearn T; Lunetta KL; Zirpoli G; Troester MA; Ruiz-Narváez EA; Haddad SA; PalChoudhury P; Figueroa J; John EM; Bernstein L; Zheng W; Hu JJ; Ziegler RG; Nyante S; Bandera EV; Ingles SA; Mancuso N; Press MF; Deming SL; Rodriguez-Gil JL; Yao S; Ogundiran TO; Ojengbe O; Bolla MK; Dennis J; Dunning AM; Easton DF; Michailidou K; Pharoah PDP; Sandler DP; Taylor JA; Wang Q; Weinberg CR; Kitahara CM; Blot W; Nathanson KL; Hennis A; Nemesure B; Ambs S; Sucheston-Campbell LE; Bensen JT; Chanock SJ; Olshan AF; Ambrosone CB; Olopade OI; Yarney J; Awuah B; Wiafe-Addai B; Conti DV; ; Palmer JR; Garcia-Closas M; Huo D; Haiman CA
    J Natl Cancer Inst; 2021 Sep; 113(9):1168-1176. PubMed ID: 33769540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.
    Pfeifer W; Sokolenko AP; Potapova ON; Bessonov AA; Ivantsov AO; Laptiev SA; Zaitseva OA; Yatsuk OS; Matsko DE; Semiglazova TY; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2014 Dec; 148(3):675-83. PubMed ID: 25414026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future.
    Yadav S; Couch FJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():61-74. PubMed ID: 31099663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.